Status:

COMPLETED

Hemopatch Safety and Efficacy Evaluation Versus Standard Practice for Sealing the Dura in Cerebrospinal Fluid Leaks

Lead Sponsor:

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Conditions:

Surgery

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Posterior fossa surgeries are generally complicated by difficulties in creating a watertight dural closure, which often requires the use of dural substitutes. In particular, surgical procedures at thi...

Detailed Description

Various techniques have been developed to overcome this problem and achieve a tight dural closure. Although there is published evidence showing the efficacy and safety of some of these sealants in pos...

Eligibility Criteria

Inclusion

  • Patients who are planned for non-traumatic posterior fossa surgery
  • Surgery that requires opening and closing of the dura mater.
  • Patients who have a clean surgical wound (class I surgical wound classification)
  • Patients undergoing one of the following surgical procedures:
  • Space occupant injuries (LOEs) rese dried through the following approaches:
  • Approaching the rear pit of the middle line
  • Approach to the posterior paramedian fossa
  • Approach to the cerebellar pontine angle (PC) and the back of the petrous vertex
  • Clinical diagnosis of primary Chiari 1 (CM1) malformation and scheduled decompression surgery, with evidence of NM of tonsil herniation down by an independent official radiology report.
  • Subjects who are able to provide written informed consent prior to participating in the clinical trial.
  • Be over 18 years of age.
  • Understand the purpose of the study and be available for frequent hospital visits.
  • Women of childbearing potential and males with partners of childbearing potential should commit to using a highly effective method of contraception (such as surgical sterilization, double barrier method, oral contraceptives or contraceptive hormonal implants) and to continue to use them for up to 6 months after surgery.

Exclusion

  • Patients undergoing a supratentorial surgical procedure/approach.
  • Patients undergoing any other approach/surgical procedure at the base of the skull that is not in the posterior pit:
  • Side boarding of the foramen magno: far side, extreme side, anterolateral, posterolateral,
  • Approaching the jugular foramen: infratemporal, condylar juxta, transjugular
  • Approach to the middle pit: subtemporal (+/-petrous apex perforation), pterional approach (any temporary fronto approach +/- orbitozygomatic replacement)
  • Approach to the previous pit: subfrontal (uni or bilateral)
  • Presence of hydrocephalus not resolved prior to surgery
  • Previous surgery in the posterior pit.
  • Pre-radiation therapy treatment.
  • Previous (within the last 6 months) or anticipated neurosurgical procedure involving the opening of the dura mater that may affect the safety assessment
  • \> 1 dural opening
  • Inability to understand informed consent or unwillingness to participate in the study.
  • Inability, at the time of consent, to return for follow-up evaluations after surgery
  • Evidence of spinal dysraphism.
  • Allergy, hypersensitivity or history of allergic reaction to Hemopatch or its components (to bovine proteins or bright blue dye: FD\&C blue No. 1 \[blue 1\]).
  • Evidence of an infection within 5 days prior to the start of the study.
  • Pregnancy or planning to become pregnant during the course of the study. Breast feeding

Key Trial Info

Start Date :

November 2 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 15 2024

Estimated Enrollment :

122 Patients enrolled

Trial Details

Trial ID

NCT04419597

Start Date

November 2 2020

End Date

July 15 2024

Last Update

July 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Ramón y Cajal

Madrid, Spain, 28034